Cardio-Oncology
Management of Toxicities in the Era of Immunotherapy
Series: Current Clinical Pathology;
- Publisher's listprice EUR 106.99
-
44 374 Ft (42 261 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 8 875 Ft off)
- Discounted price 35 499 Ft (33 809 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
44 374 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number 1st ed. 2022
- Publisher Springer International Publishing
- Date of Publication 10 August 2023
- Number of Volumes 1 pieces, Book
- ISBN 9783030977467
- Binding Paperback
- See also 9783030977436
- No. of pages122 pages
- Size 235x155 mm
- Weight 267 g
- Language English
- Illustrations XIV, 122 p. 21 illus., 18 illus. in color. Illustrations, black & white 477
Categories
Long description:
The development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC).
Table of Contents:
1. Background: Immunology and cancer.- 2. Available immunotherapy drugs in oncology.- 3. Immunotherapy adverse events.- 4. Pathophysiology of cardiac toxicity.- 5. Cardiac risk factors for immunotherapy.- 6. Diagnostic methods of cardiac immunotherapy damaging.- 7. Biomarkers of early cardiotoxicity.- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist.- 9. Management of patients with cardiac toxicity: the point of view of the oncologist.- 10. Future perspectives.
More
The Hidden Gender of Law
19 105 HUF
17 194 HUF
